DexCom, Inc. today issued the following statement in support of the CHIPS Act:

"Dexcom encourages Congress to swiftly pass the CHIPS Act - a legislative initiative that will incentivize, retain, and grow semiconductor manufacturing capacity and innovation in the U.S.," said Kevin Sayer, chairman, president & CEO of Dexcom. "While Dexcom is not facing a chip shortage at this time, it is important for Congress to help expand semiconductor manufacturing in the U.S. to increase long-term supply and ensure chip availability well into the future. Semiconductor technology enables our continuous glucose monitoring systems, helping the lives of more than a million people with diabetes around the world who depend on Dexcom CGM every day."

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

DexCom Inc. published this content on 22 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 July 2022 23:33:07 UTC.